Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Bladder cancer: Always consider extravesical sites when BCG fails.

× No keyword cloud information.

10 in total

1. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.

Authors: J Huguet; M Crego; S Sabaté; J Salvador; J Palou; H Villavicencio
Journal: Eur Urol Date: 2005-04-07 Impact factor: 20.096

2. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study.

Authors: D L Lamm; B A Blumenstein; J D Crissman; J E Montie; J E Gottesman; B A Lowe; M F Sarosdy; R D Bohl; H B Grossman; T M Beck; J T Leimert; E D Crawford
Journal: J Urol Date: 2000-04 Impact factor: 7.450

3. Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance.

Authors: Jorg Oddens; Maurizio Brausi; Richard Sylvester; Aldo Bono; Cees van de Beek; George van Andel; Paolo Gontero; Wolfgang Hoeltl; Levent Turkeri; Sandrine Marreaud; Sandra Collette; Willem Oosterlinck
Journal: Eur Urol Date: 2012-11-02 Impact factor: 20.096

4. Maintenance therapy with bacillus Calmette-Guérin Connaught strain clearly prolongs recurrence-free survival following transurethral resection of bladder tumour for non-muscle-invasive bladder cancer.

Authors: Shiro Hinotsu; Hideyuki Akaza; Seiji Naito; Seiichiro Ozono; Yoshiteru Sumiyoshi; Sumio Noguchi; Akito Yamaguchi; Satoshi Nagamori; Akito Terai; Yasutomo Nasu; Haruki Kume; Yoshihiko Tomita; Yoshinori Tanaka; Shoji Samma; Hirotsugu Uemura; Hirofumi Koga; Tomoyasu Tsushima
Journal: BJU Int Date: 2010-12-22 Impact factor: 5.588

5. Intravesical BCG in patients with carcinoma in situ of the urinary bladder: long-term results of EORTC GU Group phase II protocol 30861.

Authors: G Jakse; R Hall; A Bono; W Höltl; P Carpentier; J P Spaander; A P van der Meijden; R Sylvester
Journal: Eur Urol Date: 2001-08 Impact factor: 20.096

6. Extravesical tumor relapse in patients with superficial bladder tumors.

Authors: H W Herr
Journal: J Clin Oncol Date: 1998-03 Impact factor: 44.544

7. Hexylaminolaevulinate fluorescence cystoscopy in patients previously treated with intravesical bacille Calmette-Guérin.

Authors: Eleanor R Ray; Kathryn Chatterton; M Shamim Khan; Ashish Chandra; Kay Thomas; Prokar Dasgupta; Tim S O'Brien
Journal: BJU Int Date: 2009-10-13 Impact factor: 5.588

8. SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guérin.

Authors: Eila C Skinner; Bryan Goldman; Wael A Sakr; Daniel P Petrylak; Heinz-Josef Lenz; Cheryl T Lee; Shandra S Wilson; Mitchell Benson; Seth P Lerner; Cathy M Tangen; Ian M Thompson
Journal: J Urol Date: 2013-04-15 Impact factor: 7.450

9. Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer.

Authors: Seth P Lerner; Catherine M Tangen; Heidi Sucharew; David Wood; E David Crawford
Journal: Urol Oncol Date: 2008-03-04 Impact factor: 3.498

10. Bacillus Calmette-Guérin failure in patients with non-muscle-invasive urothelial carcinoma of the bladder may be due to the urologist's failure to detect urothelial carcinoma of the upper urinary tract and urethra.

Authors: Gianluca Giannarini; Frédéric D Birkhäuser; Franz Recker; George N Thalmann; Urs E Studer
Journal: Eur Urol Date: 2013-10-09 Impact factor: 20.096

10 in total